K Ullas Kamath

In an interview with CNBC-TV18, K Ullas Kamath, Joint MD and CFO of the company said that due to demonetisation sales in November saw a decline of 19 percent but it grew 14 percent in December and a similar trend is being seen for the month of January as well.

No growth in wholesale market yet, says Jyothy Labs MD

Speaking to CNBC-TV18, K Ullas Kamath, Joint MD and CFO of Jyothy Laboratories said, growth is still not there in the wholesale market.

India's consumption story to revive in H2FY17: Experts

Demand pickup is expected to start from October onwards and there are enough opportunities in the rural segment, says Saugata Gupta, MD and CEO of Marico.

Ujala has no competiton; saw good growth in Q2: Jyothy Labs

In an interview to CNBC-TV18, K Ullas Kamath, Joint MD & CFO of Jyothy Laboratories spoke about their second quarter numbers.

Eyeing EBITDA growth of 35% for FY15: Jyothy Laboratories

The company is also aiming for a top line growth of 18-20 percent for FY15.

See H2 13-14% EBITDA margin; 20% FY15 profit growth: Jyothy

K Ullas Kamath, joint managing director and CFO of Jyothy Laboratories says the company will get the benefit of softer raw material costs in the third and fourth quarter. The company‘s expenditure rose to 12.6 percent this quarter, higher than the usual 10 percent, he adds.

See 25% topline and bottomline growth in FY13: Jyothy Labs

K Ullas Kamath, deputy managing director of Jyothy Laboratories sees 25% top-line growth and 25% bottom-line growth in FY13.

Expect 25% growth in standalone profit in FY13: Jyothy Labs

K Ullas Kamath, deputy managing director, Jyothy Laboratories says, he expects the company to grow standalone top-line and bottom-line by 25% for the entire year.

See around 20-25% growth in Henkel's biz ahead: Jyothy Labs

K Ullas Kamath, deputy managing director of Jyothy Laboratories says, he expects minimum of 20-25% growth in Henkel’s business going forward.

Hope to improve EBITDA margins in current year: Jyothy Labs

Jyothy Laboratories has announced its FY11 results. He further says, cost cutting measures helped maintain earnings before interest, taxes, depreciation and amortization (EBITDA) margins. The company hopes to improve EBITDA margins in the current year.

Henkel fits well with our business segments: Jyothy Labs

Mumbai-based Jyothy Laboratories has acquired a 14.9% stake in Henkel India from Tamil Nadu Petro Products for Rs 60.73 crore in an all-cash deal.